Assyro AI

Orange Book product · Brand (NDA)

ORLADEYO

BEROTRALSTAT DIHYDROCHLORIDE

Brand (NDA)NDA 219776RX BIOCRYST

At a glance

Dec 11, 2025

Approved

Brand (NDA)

Application

Not listed

TE code

22

Listed patents

Key dates

  1. Approval

    FDA approval date of this drug product.

    Dec 11, 2025

    6 mo ago

  2. Today

  3. Exclusivity ends · NP

    New product exclusivity (3 years)

    Dec 11, 2028

    in 2 yr 6 mo

  4. Exclusivity ends · PED

    Pediatric exclusivity (adds 6 months)

    Jun 11, 2029

    in 3 yr

  5. Patent 10329260 expires

    Listed drug substance patent expiration.

    Mar 09, 2035

    in 8 yr 10 mo

  6. Patent 10689346 expires

    Listed method-of-use patent (U-4535) expiration.

    Mar 09, 2035

    in 8 yr 10 mo

  7. Patent 11230530 expires

    Listed method-of-use patent (U-4535) expiration.

    Mar 09, 2035

    in 8 yr 10 mo

  8. Patent 11708333 expires

    Listed method-of-use patent (U-4535) expiration.

    Mar 09, 2035

    in 8 yr 10 mo

  9. Patent 12116346 expires

    Listed drug substance patent expiration.

    Mar 09, 2035

    in 8 yr 10 mo

  10. Patent 10125102 expires

    Listed drug substance patent expiration.

    Apr 07, 2035

    in 8 yr 11 mo

  11. Patent 10662160 expires

    Listed drug substance patent expiration.

    Nov 01, 2039

    in 13 yr 7 mo

  12. Patent 11117867 expires

    Listed drug product patent expiration.

    Nov 01, 2039

    in 13 yr 7 mo

  13. Patent 11618733 expires

    Listed method-of-use patent (U-4535) expiration.

    Nov 01, 2039

    in 13 yr 7 mo

  14. Patent 12344585 expires

    Listed method-of-use patent (U-4535) expiration.

    Nov 01, 2039

    in 13 yr 7 mo

  15. Patent 12545645 expires

    Listed drug substance patent expiration.

    Nov 01, 2039

    in 13 yr 7 mo

  16. Patent 12545646 expires

    Listed drug substance patent expiration.

    Nov 01, 2039

    in 13 yr 7 mo

  17. Patent 12545647 expires

    Listed drug substance patent expiration.

    Nov 01, 2039

    in 13 yr 7 mo

  18. Patent 12552750 expires

    Listed drug substance patent expiration.

    Nov 01, 2039

    in 13 yr 7 mo

  19. Patent 12590068 expires

    Listed drug substance patent expiration.

    Nov 01, 2039

    in 13 yr 7 mo

  20. Patent 12590069 expires

    Listed drug substance patent expiration.

    Nov 01, 2039

    in 13 yr 7 mo

  21. Patent 12545645*PED expires

    Listed listed patent expiration.

    May 01, 2040

    in 14 yr 1 mo

  22. Patent 12545646*PED expires

    Listed listed patent expiration.

    May 01, 2040

    in 14 yr 1 mo

  23. Patent 12545647*PED expires

    Listed listed patent expiration.

    May 01, 2040

    in 14 yr 1 mo

  24. Patent 12552750*PED expires

    Listed listed patent expiration.

    May 01, 2040

    in 14 yr 1 mo

  25. Patent 12590068*PED expires

    Listed listed patent expiration.

    May 01, 2040

    in 14 yr 1 mo

  26. Patent 12590069*PED expires

    Listed listed patent expiration.

    May 01, 2040

    in 14 yr 1 mo

Pharmaceutical detail

Active ingredient

BEROTRALSTAT DIHYDROCHLORIDE

Strength

EQ 96MG BASE/PACKET

Dosage form

PELLETS

Route

ORAL

TE code

Not listed

Application

NDA 219776

Product number

002

Marketing status

RX

Reference listed drug (RLD)

Yes

Reference standard (RS)

No

Active-ingredient family

View full family

This is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.

Marketing exclusivity (2)

  • NPNew product exclusivity (3 years)

    Dec 11, 2028

    in 2 yr 6 mo

  • PEDPediatric exclusivity (adds 6 months)

    Jun 11, 2029

    in 3 yr

Listed patents (22)

Patents listed in the FDA Orange Book for this product, with expiration date and patent type.
PatentExpiresInType
10329260Mar 09, 2035in 8 yr 10 mo
Substance
10689346Mar 09, 2035in 8 yr 10 mo
U-4535
11230530Mar 09, 2035in 8 yr 10 mo
U-4535
11708333Mar 09, 2035in 8 yr 10 mo
U-4535
12116346Mar 09, 2035in 8 yr 10 mo
Substance
10125102Apr 07, 2035in 8 yr 11 mo
SubstanceU-4535
10662160Nov 01, 2039in 13 yr 7 mo
SubstanceU-4535
11117867Nov 01, 2039in 13 yr 7 mo
ProductU-4535
11618733Nov 01, 2039in 13 yr 7 mo
U-4535
12344585Nov 01, 2039in 13 yr 7 mo
U-4535
12545645Nov 01, 2039in 13 yr 7 mo
SubstanceProduct
12545646Nov 01, 2039in 13 yr 7 mo
SubstanceProduct
12545647Nov 01, 2039in 13 yr 7 mo
SubstanceProduct
12552750Nov 01, 2039in 13 yr 7 mo
SubstanceProduct
12590068Nov 01, 2039in 13 yr 7 mo
SubstanceProduct
12590069Nov 01, 2039in 13 yr 7 mo
SubstanceProduct
12545645*PEDMay 01, 2040in 14 yr 1 mo
12545646*PEDMay 01, 2040in 14 yr 1 mo
12545647*PEDMay 01, 2040in 14 yr 1 mo
12552750*PEDMay 01, 2040in 14 yr 1 mo
12590068*PEDMay 01, 2040in 14 yr 1 mo
12590069*PEDMay 01, 2040in 14 yr 1 mo
Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.